Abstract: OBJECTIVE To evaluate the efficacy and safety of nifuratel-nysfungin suppository in the treatment of bacterial vaginosis. METHODS A randomized and controlled clinical trial was conducted. The 80 patients in trial group were treated with nifuratel-nysfungin suppository and 78 patients in control group were given metronidazole suppository. Six successive days were taken as a course for nifuratel-nysfungin suppository group and seven successive days for metronidazole suppository. The efficacy and safety were observed respectively 3-5 d after treatment and 3-7 d after menorrhea. RESULTS The efficacy rate was 90.0% in trial group and 82.5% in control group on 3-5 d after treatment (P>0.05). There was no significant difference in clinical efficacy between two groups(P>0.05). The efficacy rate was 82.5% in trial group and 73.1% in control group on 3-7 d after menorrhea (P>0.05). There was no significant difference in clinical efficacy between two groups (P>0.05). No severe adverse reactions were found in the trial. The adverse reactions incidence in trial group was lower than that in control group(P<0.5). CONCLUSION Nifuratel-nysfungin suppository is an effective and safe preparation in the treatment of bacterial vaginosis.